Integrative Bioinformatics Links HNF1B with Clear Cell Carcinoma and Tumor-Associated Thrombosis

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Cuff, Justin ^a   Salari, Keyan ^a,b   Clarke, Nicole ^a   Esheba, Ghada E ^a,c   Forster, Andrew D ^a   Huang, Stephanie ^a   West, Robert B ^a   Higgins, John P ^a   Longacre, Teri A ^a   Pollack, Jonathan R ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c TANTA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13; FIBRINOGEN; HEPATOCYTE NUCLEAR FACTOR 1BETA; PROTHROMBIN;

ARTICLE; BINDING SITE; CEREBROVASCULAR ACCIDENT; CLEAR CELL CARCINOMA; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; G6PC GENE; GENE; GLYCOGEN METABOLISM; GYNECOLOGIC CANCER; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG EMBOLISM; PHENOTYPE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RISK FACTOR; THROMBOSIS; UPREGULATION; VENOUS THROMBOEMBOLISM;

ADENOCARCINOMA, CLEAR CELL; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; CARCINOMA, RENAL CELL; COMPUTATIONAL BIOLOGY; DNA METHYLATION; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE-6-PHOSPHATASE; GLYCOGEN; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; RISK; VENOUS THROMBOSIS;

EID: 84883607301     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074562     Document Type: Article

References (61)

1. Pectasides D, Pectasides E, Psyrri A, Economopoulos T, (2006) Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist 11: 1089-1094.
2. Norris HJ, Robinowitz M, (1971) Ovarian adenocarcinoma of mesonephric type. Cancer 28: 1074-1081.
3. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, et al. (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62: 4722-4729.
4. Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, et al. (2003) Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 163: 2503-2512.
5. Kato N, Sasou S, Motoyama T, (2006) Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol 19: 83-89.
6. Yamamoto S, Tsuda H, Aida S, Shimazaki H, Tamai S, et al. (2007) Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol 38: 1074-1080.
7. Terasawa K, Toyota M, Sagae S, Ogi K, Suzuki H, et al. (2006) Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines. Br J Cancer 94: 914-921.
8. Kato N, Tamura G, Motoyama T, (2008) Hypomethylation of hepatocyte nuclear factor-1beta (HNF-1beta) CpG island in clear cell carcinoma of the ovary. Virchows Arch 452: 175-180.
9. Cillo C, Faiella A, Cantile M, Boncinelli E, (1999) Homeobox genes and cancer. Exp Cell Res 248: 1-9.
10. Tronche F, Yaniv M, (1992) HNF1, a homeoprotein member of the hepatic transcription regulatory network. Bioessays 14: 579-587.
11. Cereghini S, Ott MO, Power S, Maury M, (1992) Expression patterns of vHNF1 and HNF1 homeoproteins in early postimplantation embryos suggest distinct and sequential developmental roles. Development 116: 783-797.
12. Coffinier C, Barra J, Babinet C, Yaniv M, (1999) Expression of the vHNF1/HNF1beta homeoprotein gene during mouse organogenesis. Mech Dev 89: 211-213.
13. Haumaitre C, Fabre M, Cormier S, Baumann C, Delezoide AL, et al. (2006) Severe pancreas hypoplasia and multicystic renal dysplasia in two human fetuses carrying novel HNF1beta/MODY5 mutations. Hum Mol Genet 15: 2363-2375.
14. Horikawa Y, Iwasaki N, Hara M, Furuta H, Hinokio Y, et al. (1997) Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet 17: 384-385.
15. Bellanne-Chantelot C, Chauveau D, Gautier JF, Dubois-Laforgue D, Clauin S, et al. (2004) Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations. Ann Intern Med 140: 510-517.
16. Edghill EL, Bingham C, Ellard S, Hattersley AT, (2006) Mutations in hepatocyte nuclear factor-1beta and their related phenotypes. J Med Genet 43: 84-90.
17. Haumaitre C, Barbacci E, Jenny M, Ott MO, Gradwohl G, et al. (2005) Lack of TCF2/vHNF1 in mice leads to pancreas agenesis. Proc Natl Acad Sci U S A 102: 1490-1495.
18. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, et al. (2007) Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 39: 977-983.
19. Sun J, Zheng SL, Wiklund F, Isaacs SD, Purcell LD, et al. (2008) Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet 40: 1153-1155.
20. Lowe HJ, Ferris TA, Hernandez PM, Weber SC, (2009) STRIDE-An integrated standards-based translational research informatics platform. AMIA Annu Symp Proc 2009: 391-395.
21. Stenberg LM, Brown MA, Nilsson E, Ljungberg O, Stenflo J, (2001) A functional prothrombin gene product is synthesized by human kidney cells. Biochem Biophys Res Commun 280: 1036-1041.
22. Matys V, Fricke E, Geffers R, Gossling E, Haubrock M, et al. (2003) TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res 31: 374-378.
23. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
24. Senkel S, Lucas B, Klein-Hitpass L, Ryffel GU, (2005) Identification of target genes of the transcription factor HNF1beta and HNF1alpha in a human embryonic kidney cell line. Biochim Biophys Acta 1731: 179-190.
25. Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, et al. (2006) Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 66: 1354-1362.
26. Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, et al. (2011) Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One 6: e21121.
27. Esteller M, (2008) Epigenetics in cancer. N Engl J Med 358: 1148-1159.
28. Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, et al. (1996) Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 60: 412-417.
29. Recio FO, Piver MS, Hempling RE, Driscoll DL, (1996) Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 78: 2157-2163.
30. Kobel M, Kalloger SE, Carrick J, Huntsman D, Asad H, et al. (2009) A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 33: 14-21.
31. Chou JY, Mansfield BC, (2008) Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease. Hum Mutat 29: 921-930.
32. Dahlback B, (2000) Blood coagulation. Lancet 355: 1627-1632.
33. Varki A, (2007) Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 110: 1723-1729.
34. Levine M, (1997) Treatment of thrombotic disorders in cancer patients. Haemostasis 27Suppl 1: 38-43.
35. Prandoni P, Falanga A, Piccioli A, (2005) Cancer and venous thromboembolism. Lancet Oncol 6: 401-410.
36. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, et al. (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78: 285-291.
37. Donati MB, (1995) Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. Thromb Haemost 74: 278-281.
38. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL, (1998) The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 338: 1169-1173.
39. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH, (2007) Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110: 2339-2346.
40. Tsimafeyeu IV, Demidov LV, Madzhuga AV, Somonova OV, Yelizarova AL, (2009) Hypercoagulability as a prognostic factor for survival in patients with metastatic renal cell carcinoma. J Exp Clin Cancer Res 28: 30.
41. Anderson FA Jr, Spencer FA, (2003) Risk factors for venous thromboembolism. Circulation 107: I9-16.
42. Reitsma PH, Versteeg HH, Middeldorp S, (2012) Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol 32: 563-568.
43. Gale AJ, Gordon SG, (2001) Update on tumor cell procoagulant factors. Acta Haematol 106: 25-32.
44. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88: 3698-3703.
45. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briet E, et al. (1994) Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms-the Leiden Thrombophilia Study (LETS). Thromb Haemost 71: 719-722.
46. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, et al. (1999) Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 81: 680-683.
47. Chew HK, Wun T, Harvey D, Zhou H, White RH, (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166: 458-464.
48. Lee AY, (2010) Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants. Hematology Am Soc Hematol Educ Program 2010: 144-149.
49. Rebouissou S, Vasiliu V, Thomas C, Bellanne-Chantelot C, Bui H, et al. (2005) Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. Hum Mol Genet 14: 603-614.
50. Garraway LA, Sellers WR, (2006) Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer 6: 593-602.
51. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436: 117-122.
52. Kwei KA, Kim YH, Girard L, Kao J, Pacyna-Gengelbach M, et al. (2008) Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 27: 3635-3640.
53. Suehiro Y, Sakamoto M, Umayahara K, Iwabuchi H, Sakamoto H, et al. (2000) Genetic aberrations detected by comparative genomic hybridization in ovarian clear cell adenocarcinomas. Oncology 59: 50-56.
54. Behbakht K, Randall TC, Benjamin I, Morgan MA, King S, et al. (1998) Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 70: 255-258.
55. Jenison EL, Montag AG, Griffiths CT, Welch WR, Lavin PT, et al. (1989) Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol 32: 65-71.
56. Jiang X, Morland SJ, Hitchcock A, Thomas EJ, Campbell IG, (1998) Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 58: 1707-1712.
57. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, et al. (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363: 1532-1543.
58. Fowler DJ, Nicolaides KH, Miell JP, (2000) Insulin-like growth factor binding protein-1 (IGFBP-1): a multifunctional role in the human female reproductive tract. Hum Reprod Update 6: 495-504.
59. Fazleabas AT, Kim JJ, Strakova Z (2004) Implantation: embryonic signals and the modulation of the uterine environment-a review. Placenta 25 Suppl A: S26-31.
60. Milwidsky A, Palti Z, Gutman A, (1980) Glycogen metabolism of the human endometrium. J Clin Endocrinol Metab 51: 765-770.
61. Lockwood CJ, (2006) Pregnancy-associated changes in the hemostatic system. Clin Obstet Gynecol 49: 836-843.